DOCSLIB.ORG

Hyalofill: a New Product for Chronic Wound Management Mike Edmonds, Ali Foster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyalofill: a New Product for Chronic Wound Management Mike Edmonds, Ali Foster Product Focus Hyalofill: a new product for chronic wound management Mike Edmonds, Ali Foster Introduction ARTICLE POINTS TM Hyalofill has been launched recently as a wound care treatment for Hyalofill is a TM the management of chronic wounds. Hyalofill consists of HYAFF , 1new product for a derivative of hyaluronic acid. The wound healing effects of Hyalofill may the management of be attributed to its tissue organising role and its remarkable chronic wounds. hydroregulatory properties, which help to produce a moist environment conducive to wound healing. Hyalofill is 2available in dressing or rope form. yalofill is a new wound care HA has an identical structure in all treatment for the management of species and is completely conserved through The active chronic wounds, including diabetic evolution. Hence, it is of fundamental 3ingredient of H biological importance. Hyalofill is hyaluronic foot ulcers. It is a cream-coloured non- acid. adherent fleece which is placed in direct contact with the wound bed of an ulcer Hyalofill in use Hyaluronic acid or can be used to lightly pack sinuses. It is Application of HA to human chronic 4is a highly conserved available either as a flat sheet (Hyalofill-F) wounds, such as venous leg ulcers, has molecule occurring or as a rope (Hyalofill-R). been shown to promote healing (Ortonne, in many species, with 1996). multiple functions. Structure and function In its natural state, HA is a gel that is difficult Hyalofill is made of a unique biomaterial to process and sterilise. It is degraded Hyalofill may called HYAFF. This is a stable biocompatible in vivo and breaks down rapidly when 5be more useful for derivative of hyaluronic acid (HA), a major applied to wounds. To increase stability, ulcers complicated by component of the extracellular matrix. HA HYAFF was produced from HA via a sinuses and fistulae and is a linear polysaccharide that can absorb chemical esterification reaction linking it to deep exudating wounds. up to 3000 times its own weight in water; a benzyl alcohol. When HYAFF comes into it is nature’s moisturiser and the body’s contact with serum of wound exudate, a KEY WORDS hydroregulator. Other properties include hydrophilic gel is produced. The gel overlays l Hyalofill free radical scavenging. HA is present in the wound and creates an HA-rich tissue l Hyaluronic acid many tissues and its functions include: interface, thereby providing a moist wound l Chronic wounds l Facilitation of growth and movement of environment conducive to granulation and l Sinuses fibroblasts healing. Hyalofill is 75% esterified and is l Cushioning in the eyes presented in the form of a non-woven fleece. l Lubrication in the synovial fluid HYAFF is broken down to HA and benzyl l Role in cell mitosis and migration alcohol; the latter is metabolised to hippuric l Control of extracellular matrix acid and excreted in the urine. hydration and osmoregulation (Chen and Hyalofill is straightforward to use. It can Abatangelo, 1999) be stored in the clinic cupboard and used l Regulation of inflammation. as needed. Hyalofill should only be applied Angiogenesis, an essential step in the to clean wounds; necrotic and sloughy natural process of wound healing, is strongly wounds should therefore be debrided before induced by degradation products of HA application. (West et al, 1985). Once infection has been controlled and HA may play a critical role in influencing any obviously dead bone removed, the Mike Edmonds is the location of capillary networks (Fienberg sinus can be lightly packed with HYAFF to Consultant Physician and Ali Foster is Chief Podiatrist at and Beebe, 1983). stimulate closure. King’s College Hospital, London The Diabetic Foot Vol 3 No 1 2000 29 HYALOFILL: A NEW PRODUCT FOR CHRONIC WOUND MANANAGEMENT Excised metatarsal head. Hyalofill applied to wound. Healed wound, after treatment. The wound site should be cleaned and group, there were 9 ulcers with sinuses and the surrounding skin should be dry. Hyalofill 9 with bone exposed. In the active group is placed onto the surface of the wound and 12 of the 13 sinuses healed compared with covered with a sterile secondary dressing. only 1 of 9 in the control group (P<0.01). In the authors’ practice, a secondary foam In the active group, 10 of the 15 ulcers dressing has been used for the diabetic foot. healed, compared with 3 of 15 in the The interval between dressing changes control group (P<0.05). Thus, HYAFF will depend on the amount of exudate application resulted in a higher degree of produced and the stage of wound healing. closure of sinuses and improved healing of In the authors’ practice, it is standard to indolent neuropathic ulcers. lift the secondary dressing daily to assess Hyalofill is now available in the UK. progress in the wound. Ideally, Hyalofill Although evidence on its use in diabetic PAGE POINTS should be applied every three days to maintain foot lesions is limited and more research an HA-rich tissue interface, although in an is needed, early clinical experience suggests Frequency of outpatient setting a weekly change may be that it may prove useful for the treatment changing Hyalofill 1 appropriate. When changing the wound of ulcers complicated by sinuses and dressings depends on the n amount of exudate dressing, residual Hyalofill is easily removed fistulae, and deep exudating wounds. by irrigating the wound with sterile saline. produced and stage of Hyalofill and HYAFF are registered trademarks of Fidia healing. Advance Biopolymers srl. E.R. Squibb, ConvaTec are Clinical evidence on Hyalofill licensed users. Hyalofill has Recent studies have shown that pre - Chen WYJ, Abatangelo G (1999) Functions of recently been 2 treatment of full-thickness wounds with an hyaluronan in wound repair. Wound Repair and launched in the UK. esterified HA results in a better organised Regeneration 7: 79–89 dermis and vascularity, with evidence of Fienberg RN, Beebe DC (1983) Hyaluronate in vasculogenesis. Science 220: 1177 –9 Although evidence on angiogenesis (Navsaria et al, 1998). Foster AM, Bates M, Doxford M, Edmonds ME (1999) 3the use of Hyalofill In a recent randomised controlled study, The treatment of indolent neuropathic ulceration in diabetic foot lesions of the diabetic foot with Hyaff. Diabetic Medicine HYAFF was used in patients with diabetes : S94 is limited, early clinical 16 and indolent neuropathic ulcers (Foster et Navsaria HA, Harris P, Dona M, Bigon E, Duca M experience suggests that (1998) Hyalofill significantly improves the take rates it may be useful in the al, 1999). Of 30 patients in the study, 15 of cultured keratinocytes. Poster at European Tissue received HYAFF plus standard treatment Repair Society Meeting (August 1998) treatment of ulcers Ortonne JP (1996) A controlled study of the activity complicated by sinuses (active group), and 15 received standard of hyaluronic acid in the treatment of venous leg and fistulae, and deep treatment alone (control). In the active ulcers. Journal of Dermatological Treatment 7: 75–81 West DC, Hampsom LN, Arnold F, Kumar S (1985) exudating wounds. group, there were 13 ulcers with sinuses Angiogenesis induced by degradation products of and 13 with bone exposed. In the control hyaluronic acid. Science 228: 1324–6 30 The Diabetic Foot Vol 3 No 1 2000.
Load more

Recommended publications
  • Wound Bed Preparation: TIME in Practice
    Clinical PRACTICE DEVELOPMENT Wound bed preparation: TIME in practice Wound bed preparation is now a well established concept and the TIME framework has been developed as a practical tool to assist practitioners when assessing and managing patients with wounds. It is important, however, to remember to assess the whole patient; the wound bed preparation ‘care cycle’ promotes the treatment of the ‘whole’ patient and not just the ‘hole’ in the patient. This paper discusses the implementation of the wound bed preparation care cycle and the TIME framework, with a detailed focus on Tissue, Infection, Moisture and wound Edge (TIME). Caroline Dowsett, Heather Newton dependent on one another. Acute et al, 2003). Wound bed preparation wounds usually follow a well-defined as a concept allows the clinician to KEY WORDS process described as: focus systematically on all of the critical Wound bed preparation 8Coagulation components of a non-healing wound to Tissue 8Inflammation identify the cause of the problem, and Infection 8Cell proliferation and repair of implement a care programme so as to Moisture the matrix achieve a stable wound that has healthy 8Epithelialisation and remodelling of granulation tissue and a well vascularised Edge scar tissue. wound bed. In the past this model of healing has The TIME framework been applied to chronic wounds, but To assist with implementing the he concept of wound bed it is now known that chronic wound concept of wound bed preparation, the preparation has gained healing is different from acute wound TIME acronym was developed in 2002 T international recognition healing. Chronic wounds become ‘stuck’ by a group of wound care experts, as a framework that can provide in the inflammatory and proliferative as a practical guide for use when a structured approach to wound stages of healing (Ennis and Menses, managing patients with wounds (Schultz management.
    [Show full text]
  • Understand Your Chronic Wound
    Patient Information Leaflet Understanding your Chronic Wound Dressings, management and wound infection In this leaflet Health Care Professional (HCP) refers to any member of the team involved in your wound care. This can include treatment room or practice nurse, community, ward or clinic nurse, GP or hospital doctor, podiatrist etc. Chronic Wounds and Dressings What is a Chronic wound? A wound with slow progress towards healing or shows delayed healing. This may be due to underlying issues such as: • Poor blood flow and less oxygen getting to the wound • Other health conditions • Poor diet, smoking, pressure on the wound e.g. footwear/seating. Can my wound be left open to the air? No, the evidence shows that wounds heal better when the surface is kept moist (not too wet or dry). The moisture provides the correct environment to aid your wound to heal. Does my dressing need changed daily? Not usually, your HCP will explain how often it needs changed. This will depend on the level of fluid leaking from your wound. Some dressings can be left in place up to a week. Most wounds have a slight odour, but if a wound smells bad it could be a sign that something is wrong. See section on wound infection. Your dressing may indicate that it needs changed when the dark area in the centre gets close to the edge of the dressing pad. The dark area is fluid from your wound, this is normal. It will be dry to touch. Let your HCP know if your dressing needs changed before your next visit or appointment is due.
    [Show full text]
  • Guideline: Wound Bed Preparation for Healable and Non Healable Wounds
    British Columbia Provincial Nursing Skin and Wound Committee Guideline: Wound Bed Preparation for Healable and Non Healable Wounds Developed by the BC Provincial Nursing Skin and Wound Committee in collaboration with Wound Clinicians from: / TITLE Guideline: Wound Bed Preparation for Healable and Non-Healable Wounds in Adults & Children1 Practice Level Nurses in accordance with health authority and agency policy. Conservative sharp wound debridement (CSWD) is a restricted activity according to the Nurse’s (Registered) and Nurse Practitioner Regulation. 2 CRNBC states that registered nurses must successfully complete additional education and follow an established guideline when carrying out CSWD. Biological debridement therapy is a restricted activity according to the Nurse’s (Registered) and Nurse Practitioner Regulation. 3 CRNBC states that registered nurses must follow an established guideline when carrying out biological debridement. Clients 4 with wounds needing wound bed preparation require an interprofessional approach to provide comprehensive, evidence-based assessment and treatment. This clinical practice guideline focuses solely on the role of the nurse, as one member of the interprofessional team providing care to these clients. Background Factors affecting wound healability include the presence of adequate circulation in the area of the wound, wound related factors such as the size and duration of the wound, the ability to treat the cause of the wound and the presence of risk factors impacting wound healing. While many wounds heal, others are determined to be non-healing or slow-to-heal based on the presence or absence of these factors. Wound healability must be determined prior to debridement and moist wound healing. Although wound healing normally occurs in a predictable fashion, wound healing trajectories can be heterogeneous and non- uniform resulting is delayed wound healing for some clients.
    [Show full text]
  • Reactive Oxygen Species (ROS)
    EuropeanN Bryan etCells al. and Materials Vol. 24 2012 (pages 249-265) Reactive DOI: 10.22203/eCM.v024a18oxygen species in inflammation and ISSN wound 1473-2262 healing REACTIVE OXYGEN SPECIES (ROS) – A FAMILY OF FATE DECIDING MOLECULES PIVOTAL IN CONSTRUCTIVE INFLAMMATION AND WOUND HEALING Nicholas Bryan1*, Helen Ahswin2, Neil Smart3, Yves Bayon2, Stephen Wohlert2 and John A. Hunt1 1Clinical Engineering, UKCTE, UKBioTEC, The Institute of Ageing and Chronic Disease, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3GA, UK 2Covidien – Sofradim Production, 116 Avenue du Formans – BP132, F-01600 Trevoux, France 3Royal Devon & Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK Abstract Introduction Wound healing requires a fine balance between the positive The survival and longevity of any animal requires an active and deleterious effects of reactive oxygen species (ROS); vigilant set of defence mechanisms to combat infection, a group of extremely potent molecules, rate limiting in efficiently repair damaged tissue and remove debris successful tissue regeneration. A balanced ROS response associated with apoptotic/necrotic cells. Compromised will debride and disinfect a tissue and stimulate healthy tissue rapidly results in decreased mobility, organ failures, tissue turnover; suppressed ROS will result in infection hypovolaemia, hypermetabolism, and ultimately infection and an elevation in ROS will destroy otherwise healthy and sepsis. Therefore, mammals have evolved an array stromal tissue. Understanding and anticipating the ROS of physiological pathways and mechanisms that enable niche within a tissue will greatly enhance the potential to damaged tissue to return to a basal homeostatic state. In exogenously augment and manipulate healing. an ideal scenario this occurs without compromise of tissue Tissue engineering solutions to augment successful mechanics, scarring or incorporation of microbial material.
    [Show full text]
  • The Role of Antioxidants on Wound Healing: a Review of the Current Evidence
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 15 July 2021 doi:10.20944/preprints202107.0361.v1 Review THE ROLE OF ANTIOXIDANTS ON WOUND HEALING: A REVIEW OF THE CURRENT EVIDENCE. Inés María Comino-Sanz 1*, María Dolores López-Franco1, Begoña Castro2, Pedro Luis Pancorbo-Hidalgo1 1 Department of Nursing, Faculty of Health Sciences, University of Jaén, 23071 Jaén (Spain); [email protected] (IMCS); MDLP ([email protected]); PLPH ([email protected]). 2 Histocell S.L., Bizkaia Science and Technology Park, Derio, Bizkaia (Spain); [email protected] * Correspondence: [email protected]; Tel.: +34-953213627 Abstract: (1) Background: Reactive oxygen species (ROS) play a crucial role in the preparation of the normal wound healing response. Therefore, a correct balance between low or high levels of ROS is essential. Antioxidant dressings that regulate this balance is a target for new therapies. The pur- pose of this review is to identify the compounds with antioxidant properties that have been tested for wound healing and to summarize the available evidence on their effects. (2) Methods: A litera- ture search was conducted and included any study that evaluated the effects or mechanisms of an- tioxidants in the healing process (in vitro, animal models, or human studies). (3) Results: Seven compounds with antioxidant activity were identified (Curcumin, N-acetyl cysteine, Chitosan, Gallic Acid, Edaravone, Crocin, Safranal, and Quercetin) and 46 studies reporting the effects on the healing process of these antioxidants compounds were included. (4) Conclusions: These results highlight that numerous novel investigations are being conducted to develop more efficient systems for wound healing activity. The application of antioxidants is useful against oxidative damage and ac- celerates wound healing.
    [Show full text]
  • Venous Ulcer Assessment and Management: Using the Updated CEAP Classification System
    Practice Points Venous Ulcer Assessment and Management: Using the Updated CEAP Classification System Cathy Thomas Hess, BSN, RN, CWCN ylastcolumn,Classification of Pressure Injuries, Although most leg ulcers are venous ulcers, the clini- discussed the importance of documenting the cian should suspect other causes when the wound looks details of pressure injuries using the updated atypical (presence of necrotic tissue, exposed tendon, M pressure injury classification system. This livedo reticularis on surrounding skin, or a deep, column discusses the updated classification system for “punched-out” ulcer), has been present for longer than venous ulcers, namely, the Clinical Etiology Anatomy 6 months, or has not responded to good care. Do not Pathophysiology (CEAP) classification system. To under- hesitate to take a biopsy when in doubt. stand the use of this classification, let’sbrieflydiscussthe Visual and palpable assessment may not be enough etiology, assessment, and management of venous ulcers. to determine the next steps. Objective testing may be needed to confirm the diagnosis, determine the etiology ETIOLOGY of the problem, and identify the anatomic site and sever- Venous ulcers are believed to account for approximately ity of disease pathway (Table). 70% to 90% of chronic leg ulcers.1 The incidence of ve- nous ulceration increases with age, and women are three times more likely than men to develop venous leg ulcers.2 Table. CLINICAL FINDINGS ASSOCIATED WITH VENOUS In some studies, 50% of patients had venous ulcers that LEG ULCERS persisted for more than 9 months, and 20% had ulcers Wound location 30%–40% occur superior to the medial malleolus (near the that did not heal for more than 2 years.
    [Show full text]
  • Products & Technology Wound Inflammation and the Role of A
    Products & technology Wound inflammation and the role of a multifunctional polymeric dressing Temporary inflammation is a normal response in acute wound healing. However, in chronic wounds, the inflammatory phase is dysfunctional in nature. This results in delayed healing, and causes further problems such as increased pain, odour and Intro high levels of exudate production. It is important to choose a dressing that addresses all of these factors while meeting the patient’s needs. Multifunctional polymeric Authors: Keith F Cutting membrane dressings (e.g. PolyMem®, Ferris) can help to simplify this choice and Authors: Peter Vowden assist healthcare professionals in chronic wound care. The unique actions of xxxxx Cornelia Wiegand PolyMem® have been proven to reduce and prevent inflammation, swelling, bruising and pain to promote rapid healing, working in the deep tissues beneath the skin[1,2]. he mechanism of acute wound healing — the vascular and cellular stages. During is a well-described complex cellular vascular response, immediately on injury there is T interaction[3] that can be divided into an initial transient vasoconstriction that can be several integrated processes: haemostasis, measured in seconds. This is promptly followed inflammation, proliferation, epithelialisation by vasodilation under the influence of histamine and tissue remodeling. Inflammation is a key and nitric oxide (NO) that cause an inflow of blood. component of acute wound healing, clearing An increase in vascular permeability promotes damaged extracellular matrix, cells and debris leakage of serous fluid (protein-rich exudate) into from zones of tissue damage. This is normally a the extravascular compartment, which in turn time-limited orchestrated process. Successful increases the concentration of cells and clotting progression of the inflammatory phase allows factors.
    [Show full text]
  • Peripheral Arterial Occlusive Disease
    Peripheral Arterial Occlusive Disease - ACOI Chicago Hospitalist Meeting Davin Haraway DO,FACOI,FACCWS,RPhS Diplomate – American Board of Venous and Lymphatic Medicine Arterial Issues – Lower extremity encountered by Hospitalists • Acute arterial occlusion • More commonly however • Chronic peripheral vascular disease and manifestations • Ulcers toes, heels,ankles, legs, • Infected ulcers • Cellulitis • Diabetic foot ulcers • Claudication • Edema • Calciphylaxis • Non healing surgical wounds including , BKA,AKA,foot and ankle procedures, • Differentiating from Gout and Charcot Foot Atheroma Prevalence • Dx of PAD ranges from 1–22%, depending on population, risk factors, diagnostic tests • Asymptomatic PAD up to 6 times more common than symptomatic PAD • 8.4 million Americans >40 years old have PAD • High overlap of PAD with CAD and CVD • Prevalence of PAD in persons >70 years 5 times greater than in persons <40 years • Claudication 3-4 times more common in diabetics and 3 times more common in smokers Peripheral Arterial Disease and Intermittent Claudication • Peripheral Arterial Disease (PAD) A disorder caused by atherosclerosis that limits blood flow to the limbs. • Intermittent Claudication (IC) A symptom of PAD characterized by pain, aching, or fatigue in working skeletal muscles. IC arises when there is insufficient blood flow to meet the metabolic demands in leg muscles of ambulating patients. Pathophysiology of Intermittent Claudication • Intermittent claudication is associated with – Metabolic abnormalities stemming from reduced 1 blood flow and O2 delivery – Significant reduction (50%) in muscle fibers compared with controls2 – Smaller type I and II muscle fibers with greater arterial ischemia2 – Hyperplastic mitochondria and demyelination of nerve fibers3 1 Lundgren et al Am J Physiol. 1988;255:H1156-64.
    [Show full text]
  • Wound Bed Preparation in Practice
    POSITION DOCUMENT Wound bed preparation in practice Wound bed preparation: science applied to practice Wound bed preparation for diabetic foot ulcers Wound bed preparation for venous leg ulcers MANAGING EDITOR Suzie Calne SENIOR EDITORIAL ADVISOR Christine Moffatt Professor and Co-director, Centre for Research and Implementation of Clinical Practice, Wolfson Institute of Health Sciences, Thames Valley University, London, UK CONSULTANT EDITOR Madeleine Flanagan Principal Lecturer, Department of Continuing Professional Development, Faculty of Health and Human Sciences, University of Hertfordshire, UK EDITORIAL ADVISORS Vincent Falanga Professor of Dermatology and Biochemistry, Boston University; Chairman and Training Program Director, Roger Williams Medical Centre, Providence, Rhode Island, USA Marco Romanelli Consultant Dermatologist, Department of Dermatology, University of Pisa, Italy J Javier Soldevilla Ágreda Professor of Geriatric Care, EUE University of La Rioja, Logroño, Spain Supported by an educational Luc Téot grant from Smith & Nephew. Assistant Professor of Surgery, University Hospital, Montpellier, France Peter Vowden Consultant in General Surgery, Department of Vascular Surgery, Bradford Royal Infirmary, UK Ulrich E Ziegler The views expressed in this Senior Consultant and Plastic Surgeon, Department of Plastic and Hand Surgery, University of publication are those of the Wuerzburg, Germany authors and do not necessarily reflect those of Smith & Nephew. EDITORIAL PROJECT MANAGER Kathy Day SUB-EDITOR Ann Shuttleworth DESIGNER
    [Show full text]
  • Chronic Venous Ulcers: a Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127
    Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Comparative Effectiveness Review Number 127 Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10061-I Prepared by: Johns Hopkins University Evidence-based Practice Center Baltimore, MD Investigators Jonathan Zenilman, M.D. M. Frances Valle, D.N.P., M.S. Mahmoud B. Malas, M.D., M.H.S. Nisa Maruthur, M.D., M.H.S. Umair Qazi, M.P.H. Yong Suh, M.B.A., M.Sc. Lisa M. Wilson, Sc.M. Elisabeth B. Haberl, B.A. Eric B. Bass, M.D., M.P.H. Gerald Lazarus, M.D. AHRQ Publication No. 13(14)-EHC121-EF December 2013 Erratum January 2014 This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10061-I). The findings and conclusions in this document are those of the author(s), who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services.
    [Show full text]
  • Chronic Venous Leg Ulc Treatment: Future Er Research Needs
    Future Research Needs Paper Number 34 Chronic Venous Leg Ulcer Treatment: Future Research Needs Future Research Needs Paper Number 34 Chronic Venous Leg Ulcer Treatment: Future Research Needs Identification of Future Research Needs From Comparative Effectiveness Review No. 127 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10061-I Prepared by: Johns Hopkins University Evidence-based Practice Center Baltimore, MD Investigators: Gerald Lazarus, M.D. Fran Valle, D.N.P., M.S., C.R.N.P. Mahmoud Malas, M.D., M.H.S. Umair Qazi, M.D., M.P.H. Nisa Maruthur, M.D., M.H.S. Jonathan Zenilman, M.D. Chad Boult, M.D., M.P.H., M.B.A. David Doggett, Ph.D. Oluwakemi A. Fawole, M.B.C.H.B., M.P.H. Eric B. Bass, M.D., M.P.H. AHRQ Publication No. 13(14)-EHC034-EF November 2013 Addendum added January 2014 Addendum to Future Research Needs Report for Chronic Venous Leg Ulcer Treatment This report was posted for public comment from November 4, 2013 to December 2, 2013 on the Effective Health Care Web site. We received one set of thoughtful comments from the American Physical Therapy Association. The comments were related to gaps outside the scope of the original systematic review and included: the role of exercise to optimize venous pump function, optimization of general fluid balance, occupational strategies to minimize edema, inclusion of strategies for debridement and predisposing factors for venous ulcers which are located at the level of the malleoli and above.
    [Show full text]
  • Skin Substitutes for Treating Chronic Wounds: Technical Brief
    Technology Assessment Program Skin Substitutes for Treating Chronic Wounds Technical Brief Project ID: WNDT0818 February 2, 2020 Technology Assessment Program - Technical Brief Project ID: WNDT0818 Skin Substitutes for Treating Chronic Wounds Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA 290-2015-00005-I Prepared by: ECRI Institute - Penn Medicine Evidence-Based Practice Center Plymouth Meeting / Philadelphia, PA Investigators: D. Snyder, Ph.D. N. Sullivan, B.A. D. Margolis, M.D., Ph.D. K. Schoelles, M.D., S.M. ii Key Messages Purpose of Review To describe skin substitute products commercially available in the United States used to treat chronic wounds, examine systems used to classify skin substitutes, identify and assess randomized controlled trials (RCTs), and suggest best practices for future studies. Key Messages • We identified 76 commercially available skin substitutes to treat chronic wounds. The majority of these do not contain cells and are derived from human placental membrane (the placenta’s inner layer), animal tissue, or donated human dermis. • Included studies (22 RCTs and 3 systematic reviews) and ongoing clinical trials found during our search examine approximately 25 (33%) of these skin substitutes. • Available published studies rarely reported whether wounds recurred after initial healing. Studies rarely reported outcomes important to patients, such as return of function and pain relief. • Future studies may be improved by using a 4-week run-in period before study enrollment and at least a 12-week study period. They should also report whether wounds recur during 6-month followup.
    [Show full text]